ReviewCell division2026
The roles and pathways of Hsa_circ_0000285 in cancer: a potential target for cancer therapy.
Review in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNA (circRNA) is a unique type of non-coding RNA molecule characterized by a closed circular structure, exceptional stability, and the ability to act as miRNA sponges, thereby relieving their inhibitory effects on downstream target genes, thus regulating cancer cell growth and metastasis. Circ_0000285 is one of the recently discovered circRNAs. It is aberrantly expressed in hepatocellular carcinoma, gastric cancer, bladder cancer, nasopharyngeal carcinoma, osteosarcoma, thyroid cancer, glioma, cervical cancer, and neuroblastoma, predominantly exhibiting upregulation. Abnormal expression of circ_0000285 is significantly associated with cancer cell growth, metastasis, and poor prognosis in cancer patients, a process mediated by circ_0000285 acting as sponges for miR-582-3p, miR-1278, miR-409-3p, miR-599, miR-127-5p, miR‑654-3p, and miR197-3p to promote the expression of downstream target genes or directly regulate target gene expression. Therefore, this review aims to summarize the expression, function, mechanisms, and association with poor prognostic features in cancer patients of circ_0000285, offering novel candidate target molecules for the treatment of cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.